Drug name - Veltassa

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8337824 VIFOR PHARMA Linear polyol stabilized polyfluoroacrylate compositions
May, 2030

(7 years from now)

CN103919792B VIFOR PHARMA Crosslinked Cation Exchange Polymers, Compositions And Use Thereof In A Method For Treating Hyperpotassaemia
Aug, 2029

(6 years from now)

CN102202670A VIFOR PHARMA Crosslinked Cation Exchange Polymers, Compositions And Use In Treating Hyperkalemia
Aug, 2029

(6 years from now)

CN103919792A VIFOR PHARMA Crosslinked Cation Exchange Polymers, Compositions And Use In Treating Hyperkalemia
Aug, 2029

(6 years from now)

CN102202670B VIFOR PHARMA Crosslinked Cation Exchange Polymers, Compositions And Use In Treating Hyperkalemia
Aug, 2029

(6 years from now)

EP2957286B1 VIFOR PHARMA Compositions Comprising Crosslinked Cation Exchange Polymers And Use In Treating Hyperkalemia
Aug, 2029

(6 years from now)

EP2365988A2 VIFOR PHARMA Crosslinked Cation Exchange Polymers, Compositions And Use In Treating Hyperkalemia
Aug, 2029

(6 years from now)

EP2365988B1 VIFOR PHARMA Crosslinked Cation Exchange Polymers, Compositions And Use In Treating Hyperkalemia
Aug, 2029

(6 years from now)

EP2365988B2 VIFOR PHARMA Crosslinked Cation Exchange Polymers, Compositions And Use In Treating Hyperkalemia
Aug, 2029

(6 years from now)

EP2957286A1 VIFOR PHARMA Compositions Comprising Crosslinked Cation Exchange Polymers And Use In Treating Hyperkalemia
Aug, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8475780 VIFOR PHARMA Ion binding polymers and uses thereof Mar, 2024

(1 year, 6 months from now)

US8778324 VIFOR PHARMA Ion binding polymers and uses thereof Mar, 2024

(1 year, 6 months from now)

US8287847 VIFOR PHARMA Ion binding polymers and uses thereof Mar, 2024

(1 year, 6 months from now)

US8889115 VIFOR PHARMA Ion binding polymers and uses thereof Mar, 2024

(1 year, 6 months from now)

US10485821 VIFOR PHARMA Ion binding polymers and uses thereof Mar, 2024

(1 year, 6 months from now)

US7556799 VIFOR PHARMA Ion binding polymers and uses thereof Feb, 2025

(2 years from now)

US8216560 VIFOR PHARMA Ion binding polymers and uses thereof Mar, 2027

(4 years from now)

US8282913 VIFOR PHARMA Ion binding polymers and uses thereof May, 2027

(4 years from now)

US8147873 VIFOR PHARMA Methods and compositions for treatment of ion imbalances Jun, 2028

(5 years from now)

US9925212 VIFOR PHARMA Potassium-binding agents for treating hypertension and hyperkalemia Oct, 2033

(11 years from now)

US9492476 VIFOR PHARMA Potassium-binding agents for treating hypertension and hyperkalemia Oct, 2033

(11 years from now)

US11123363 VIFOR PHARMA Potassium-binding agents for treating hypertension and hyperkalemia Oct, 2033

(11 years from now)

Drugs and Companies using PATIROMER SORBITEX CALCIUM ingredient

Treatment: Treatment of hyperkalemia

Dosage: POWDER;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 8.4GM BASE/PACKET POWDER;ORAL Prescription
EQ 16.8GM BASE/PACKET POWDER;ORAL Prescription
EQ 25.2GM BASE/PACKET POWDER;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.